blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2502897

EP2502897 - METHOD FOR PRODUCING OPTICALLY ACTIVE BICYCLO [3.1.0]HEXANE DERIVATIVE USING ENZYME [Right-click to bookmark this link]
Former [2012/39]METHOD FOR PRODUCING OPTICALLY ACTIVE BICYCLO [3.1.0]HEXANE DERIVATIVE USING OXYGEN
[2014/10]
StatusNo opposition filed within time limit
Status updated on  15.05.2015
Database last updated on 09.09.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Taisho Pharmaceutical Co., Ltd.
24-1, Takada 3-chome Toshima-ku
Tokyo 170-8633 / JP
[2012/39]
Inventor(s)01 / SASAKI, Joji
c/o TAISHO PHARMACEUTICAL CO. LTD.
24-1, Takada 3-chome
Toshima-ku
Tokyo 170-8633 / JP
 [2012/39]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[N/P]
Former [2012/39]HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München / DE
Application number, filing date10831333.918.11.2010
WO2010JP06756
Priority number, dateJP2009026282718.11.2009         Original published format: JP 2009262827
[2012/39]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011061934
Date:26.05.2011
Language:JA
[2011/21]
Type: A1 Application with search report 
No.:EP2502897
Date:26.09.2012
Language:EN
[2012/39]
Type: B1 Patent specification 
No.:EP2502897
Date:09.07.2014
Language:EN
[2014/28]
Search report(s)International search report - published on:JP26.05.2011
(Supplementary) European search report - dispatched on:EP14.03.2013
ClassificationIPC:C07C67/303, C07C69/753, C12P7/62, C07B53/00, C07B57/00, C07B61/00
[2012/39]
CPC:
C07C69/757 (EP,US); C07B53/00 (EP,US); C07B57/00 (EP,US);
C07C67/303 (EP,US); C07C67/313 (EP,US); C07C67/327 (EP,US);
C12P7/62 (EP,US); C12Y301/01003 (EP,US); C07C2602/18 (EP,US) (-)
C-Set:
C07C67/303, C07C69/757 (US,EP);
C07C67/313, C07C69/757 (EP,US);
C07C67/327, C07C69/757 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/39]
Extension statesBA11.06.2012
ME11.06.2012
TitleGerman:VERFAHREN ZUR HERSTELLUNG EINES OPTISCH AKTIVEN BICYCLO-[3.1.0-]HEXANDERIVATS MITHILFE EINES ENZYMS[2014/10]
English:METHOD FOR PRODUCING OPTICALLY ACTIVE BICYCLO [3.1.0]HEXANE DERIVATIVE USING ENZYME[2014/10]
French:PROCÉDÉ DE PRODUCTION D'UN DÉRIVÉ DE BICYCLO[3.1.0]HEXANE OPTIQUEMENT ACTIF À L'AIDE D'UNE ENZYME[2014/10]
Former [2012/39]VERFAHREN ZUR HERSTELLUNG EINES OPTISCH AKTIVEN BICYCLO-[3.1.0-]HEXANDERIVATS MITHILFE VON SAUERSTOFF
Former [2012/39]METHOD FOR PRODUCING OPTICALLY ACTIVE BICYCLO [3.1.0]HEXANE DERIVATIVE USING OXYGEN
Former [2012/39]PROCÉDÉ DE PRODUCTION D'UN DÉRIVÉ DE BICYCLO[3.1.0]HEXANE OPTIQUEMENT ACTIF À L'AIDE D'OXYGÈNE
Entry into regional phase11.06.2012Translation filed 
11.06.2012National basic fee paid 
11.06.2012Search fee paid 
11.06.2012Designation fee(s) paid 
11.06.2012Examination fee paid 
Examination procedure11.06.2012Examination requested  [2012/39]
25.09.2013Amendment by applicant (claims and/or description)
12.02.2014Communication of intention to grant the patent
16.05.2014Fee for grant paid
16.05.2014Fee for publishing/printing paid
16.05.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  12.02.2014
Opposition(s)10.04.2015No opposition filed within time limit [2015/25]
Fees paidRenewal fee
14.11.2012Renewal fee patent year 03
16.11.2013Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.11.2010
AL09.07.2014
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MK09.07.2014
MT09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
SM09.07.2014
TR09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
IE18.11.2014
LU18.11.2014
CH30.11.2014
LI30.11.2014
[2018/46]
Former [2018/30]HU18.11.2010
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MK09.07.2014
MT09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
SM09.07.2014
TR09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
IE18.11.2014
LU18.11.2014
CH30.11.2014
LI30.11.2014
Former [2016/33]HU18.11.2010
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
MT09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
SM09.07.2014
TR09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
IE18.11.2014
LU18.11.2014
CH30.11.2014
LI30.11.2014
Former [2016/32]HU18.11.2010
AT09.07.2014
BE09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
SM09.07.2014
TR09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
IE18.11.2014
LU18.11.2014
CH30.11.2014
LI30.11.2014
Former [2016/22]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
SM09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
IE18.11.2014
LU18.11.2014
BE30.11.2014
CH30.11.2014
LI30.11.2014
Former [2015/50]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SI09.07.2014
SK09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
IE18.11.2014
LU18.11.2014
BE30.11.2014
CH30.11.2014
LI30.11.2014
Former [2015/46]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SK09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
IE18.11.2014
LU18.11.2014
BE30.11.2014
CH30.11.2014
LI30.11.2014
Former [2015/33]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SK09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
LU18.11.2014
BE30.11.2014
CH30.11.2014
LI30.11.2014
Former [2015/32]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
MC09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SK09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
LU18.11.2014
BE30.11.2014
Former [2015/30]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SK09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
LU18.11.2014
BE30.11.2014
Former [2015/23]AT09.07.2014
CY09.07.2014
CZ09.07.2014
DK09.07.2014
EE09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
SK09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/22]AT09.07.2014
CY09.07.2014
DK09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
IT09.07.2014
LT09.07.2014
LV09.07.2014
NL09.07.2014
PL09.07.2014
RO09.07.2014
RS09.07.2014
SE09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/12]AT09.07.2014
CY09.07.2014
ES09.07.2014
FI09.07.2014
HR09.07.2014
LT09.07.2014
LV09.07.2014
NL09.07.2014
PL09.07.2014
RS09.07.2014
SE09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
IS09.11.2014
PT10.11.2014
Former [2015/11]CY09.07.2014
ES09.07.2014
FI09.07.2014
LT09.07.2014
PL09.07.2014
SE09.07.2014
BG09.10.2014
NO09.10.2014
GR10.10.2014
PT10.11.2014
Former [2015/10]ES09.07.2014
FI09.07.2014
LT09.07.2014
SE09.07.2014
BG09.10.2014
NO09.10.2014
Former [2015/09]FI09.07.2014
LT09.07.2014
SE09.07.2014
Former [2015/08]LT09.07.2014
Documents cited:Search[A]WO2005047215  (MERCK & CO INC [US], et al) [A] 1,2,11,12 * examples 14,15 * * page 22, scheme 2: compound 18 *;
 [E]EP2298755  (TAISHO PHARMACEUTICAL CO LTD [JP]) [E] 2,11 * paragraph [0163]; compounds 2,3' * * paragraph [0168]; table 2 * * paragraph [0176]; table 6 * * [0188]: compound 3-1' after chiral HPLC * * [0198]: compound 3-6' after chiral HPLC *;
 [A]  - THEIL, FRITZ ET AL, "Enzymes in organic synthesis. Part 1. Synthesis of (1S,4R)-(-)-4-hydroxy-2-cyclopentenyl acetate by a high enantioselective enzyme catalyzed transesterification in organic solvents", SYNTHESIS, (7), 540 -1 CODEN: SYNTBF; ISSN: 0039-7881, (1988), XP002693017 [A] 1,2,11,12 * the whole document *

DOI:   http://dx.doi.org/10.1055/s-1988-27630
International search[XP]WO2009142184  (TAISHO PHARMACEUTICAL CO LTD [JP], et al);
 [A]  - NAKAZATO ATSURO ET AL., "Synthesis, in Vitro Pharmacology, Structure-Activity Relationships, and Pharmacokinetics of 3-Alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Derivatives as Potent and Selective Group II Metabotropic Glutamate Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, (20040826), vol. 47, no. 18, pages 4570 - 4587, XP008157980

DOI:   http://dx.doi.org/10.1021/jm0400294
 [A]  - YASUHARA AKITO ET AL., "Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY, (20060515), vol. 14, no. 10, pages 3405 - 3420, XP008157938

DOI:   http://dx.doi.org/10.1016/j.bmc.2005.12.061
 [A]  - YASUHARA AKITO ET AL., "Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): A potent and orally active group II mGluR antagonist with antidepressant-like potential", BIOORGANIC & MEDICINAL CHEMISTRY, (20060615), vol. 14, no. 12, pages 4193 - 4207, XP008157987

DOI:   http://dx.doi.org/10.1016/j.bmc.2006.01.060
 [A]  - ZHANG FEI ET AL., "Enantioselective Preparation of Ring-Fused 1-Fluorocyclopropane-1-carboxylate Derivatives: En Route to mGluR 2 Receptor Agonist MGS0028", ORGANIC LETTERS, (20041014), vol. 6, no. 21, pages 3775 - 3777, XP008157968

DOI:   http://dx.doi.org/10.1021/ol0484512
 [A]  - WONG AUDREY ET AL., "Reactive resin facilitated preparation of an enantiopure fluorobicycloketone", ORGANIC & BIOMOLECULAR CHEMISTRY, (2004), no. 2, pages 168 - 174, XP008157985

DOI:   http://dx.doi.org/10.1039/B312180C
by applicantJPH0952887
 WO0200595
 WO03061698
 WO2005000790
 WO2005000791
    - SCIENCE, (1992), vol. 258, pages 597 - 603
    - TRENDS PHARMACOL. SCI., (1990), vol. 11, pages 508 - 515
    - TRENDS PHARMACOL. SCI., (1993), vol. 14, pages 13 - 20
    - J. MED. CHEM., (2004), vol. 47, pages 4570 - 4587
    - BIOORG. MED. CHEM., (2006), vol. 14, pages 3405 - 3420
    - BIOORG. MED. CHEM., (2006), vol. 14, pages 4193 - 4207
    - ORG. LETT., (2004), vol. 6, pages 3775 - 3777
    - J. MED. CHEM., (2000), vol. 43, pages 4893 - 4909
    - TETRAHEDRON, (2001), vol. 57, pages 7487 - 7493
    - ORG. BIOMOL. CHEM., (2004), vol. 2, pages 168 - 174
    - J. AM. CHEM. SOC., (1960), vol. 82, page 4328
    - ORG. SYNTH., (1962), vol. 42, page 50
    - ORG. LETT., (2005), vol. 7, page 4573
    - SYNLETT, (1995), vol. 827
    - TETRAHEDRON LETTERS, (1996), vol. 37, page 7131
    - ORG. LETT., (2000), vol. 2, page 4189
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.